TMCI trades 113.4% below Wall Street's consensus target of $8.60.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TMCI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Treace Medical Concepts, Inc. (TMCI) has a Wall Street consensus price target of $8.60, based on estimates from 9 covering analysts. With the stock currently trading at $4.03, this represents a potential upside of +113.4%. The company has a market capitalization of $261M.
Analyst price targets range from a low of $3.00 to a high of $16.00, representing a 151% spread in expectations. The median target of $6.50 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, TMCI trades at a trailing P/E of -4.7x. Analysts expect EPS to grow +7.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ANGOAngioDynamics, Inc. | $485M | $11.73 | $19.00 | +62.0% | Hold | — | 11 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 ATECAlphatec Holdings, Inc. | $1.1B | $7.44 | $13.60 | +82.8% | Buy | 25.3x | 20 |
 OSUROraSure Technologies, Inc. | $237M | $3.44 | $7.00 | +103.5% | Hold | — | 13 |
 PRCTPROCEPT BioRobotics Corporation | $1.2B | $20.62 | $23.00 | +11.5% | Buy | — | 17 |
 CNMDCONMED Corporation | $1.5B | $51.50 | $37.50 | -27.2% | Hold | 11.3x | 21 |
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.23 | $107.33 | +23.0% | Buy | 20.0x | 15 |
 IRTCiRhythm Technologies, Inc. | $3.0B | $90.22 | $169.63 | +88.0% | Buy | — | 22 |
 TMDXTransMedics Group, Inc. | $3.0B | $88.24 | $100.43 | +13.8% | Buy | 60.2x | 13 |
 ZBHZimmer Biomet Holdings, Inc. | $20.4B | $105.59 | $109.11 | +3.3% | Hold | 12.4x | 42 |
Quick answers to the most common questions about buying TMCI stock.
The consensus Wall Street price target for TMCI is $8.6, representing 113.4% upside from the current price of $4.03. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TMCI has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $8.6 implies 113.4% upside from current levels.
TMCI's current price is $4.03 with a consensus target of $8.6 (113.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $16 for TMCI, while the most conservative target is $3. The consensus of $8.6 represents the median expectation. These targets typically reflect 12-month expectations.
TMCI is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TMCI stock forecast based on 9 Wall Street analysts shows a consensus price target of $8.6, with estimates ranging from $3 (bear case) to $16 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on TMCI, with a "Hold" consensus rating and $8.6 price target (113.4% upside). 2 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TMCI analyst price targets range from $3 to $16, a 151% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8.6 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.